Russai to sell 100 million doses of Sputnik V to India

16 Sep 2020 05:54 PM

Looks like the coronavirus won't leave our backs until a potential vaccine arrives. The virus have ravaged the entire world and the cases in India have crossed 50 lakh mark.

People are dying.

However, there is some good news - Serum Institute of India has got the nod to restart their trials of Oxford's University vaccine and Russia will sell 100 million doses of it vaccine Sputnik V to India.

Russia's sovereign wealth fund has agreed a deal to sell 100 million doses of its COVID-19 vaccine Sputnik-V to India.

RDIF has tied up with Dr. Reddy’s Laboratories to conduct its clinical trials and distribution of Sputnik V vaccine in India. All we want to say is Spaciba Russia.


Clinical trials of Sputnik V to be held jointly with Dr. Reddy's Laboratories in India .

However, both the trials & supply deal depend on domestic regulatory approval.

As per the agreement RDIF will supply 100 million doses of the Covid-19 vaccine to Dr. Reddy’s.

If trials triumph vaccines will be available in India as early as November 2020.

Drugs Controller General of India has given nod to Serum Institute of India to resume clinical trial of the Oxford COVID-19 vaccine in India. Earlier, DCGI suspending phase II and III clinical trials of Oxford's Vaccine after a volunteer reportedly felt sick in UK during trials.


DCGI gives permission to SII to resume its trials on Oxford's Vaccine

Oxford vaccine is front runner jointly developed by pharma giant AstraZeneca

SII to name Oxford's vaccine Covishield in India

DCGI has put certain conditions of taking extra care during screening.

SII should keep DCGI informed and close monitoring for adverse events during follow-up.

Reporter: Sameep Narvekar | Desk: Sameep Narvekar

What do you feel

Click here